Reply to K. Altundag

Breast Cancer Res Treat. 2018 May;169(1):205. doi: 10.1007/s10549-018-4703-4. Epub 2018 Feb 6.

Authors

E A Underwood¹, M C Tierney²

Affiliations

¹ Primary Care Research Unit, Department of Family and Community Medicine, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Suite E349, Toronto, ON, M4N 3M5, Canada.
² Primary Care Research Unit, Department of Family and Community Medicine, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Suite E349, Toronto, ON, M4N 3M5, Canada. mary.tierney@sunnybrook.ca.

PMID: 29411236
DOI: 10.1007/s10549-018-4703-4

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents, Hormonal / administration & dosage
Antineoplastic Agents, Hormonal / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Breast Neoplasms / complications*
Breast Neoplasms / drug therapy
Case-Control Studies
Cognitive Dysfunction / etiology*
Female
Humans

Substances

Antineoplastic Agents, Hormonal